

Pedro R Cutillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4036158/publications.pdf>

Version: 2024-02-01

83
papers

7,837
citations

159585

30
h-index

76900

74
g-index

88
all docs

88
docs citations

88
times ranked

18555
citing authors

#	ARTICLE	IF	CITATIONS
1	Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth. <i>Journal of Pathology</i> , 2022, 256, 235-247.	4.5	7
2	Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. <i>Cell Reports</i> , 2022, 38, 110227.	6.4	33
3	Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment. <i>Cancer Research</i> , 2022, 82, 1909-1925.	0.9	13
4	Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine. <i>Methods in Molecular Biology</i> , 2022, 2420, 87-106.	0.9	3
5	Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. <i>Science Signaling</i> , 2022, 15, eabl7989.	3.6	15
6	The cytotoxic action of BCI is not dependent on its stated DUSP1 or DUSP6 targets in neuroblastoma cells. <i>FEBS Open Bio</i> , 2022, , .	2.3	4
7	eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100240.	3.8	5
8	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	8
9	Sequence and Structure-Based Analysis of Specificity Determinants in Eukaryotic Protein Kinases. <i>Cell Reports</i> , 2021, 34, 108602.	6.4	22
10	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. <i>IScience</i> , 2021, 24, 102089.	4.1	14
11	His452Tyr polymorphism in the human 5-HT2A receptor affects clozapine-induced signaling networks revealed by quantitative phosphoproteomics. <i>Biochemical Pharmacology</i> , 2021, 185, 114440.	4.4	5
12	KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas. <i>Blood</i> , 2021, 138, 370-381.	1.4	33
13	Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs. <i>Nature Communications</i> , 2021, 12, 1850.	12.8	68
14	Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans. <i>Nature Communications</i> , 2021, 12, 2028.	12.8	12
15	Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets. <i>Cancer Research</i> , 2021, 81, 5765-5776.	0.9	9
16	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 5706-5719.	0.9	64
17	Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. <i>Nature Communications</i> , 2021, 12, 5507.	12.8	15
18	Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma. <i>NAR Cancer</i> , 2021, 3, zcab009.	3.1	4

#	ARTICLE	IF	CITATIONS
19	Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3462-3462.	1.4	0
20	Targeted therapy for L1MD1-deficient non-small cell lung cancer subtypes. <i>Cell Death and Disease</i> , 2021, 12, 1075.	6.3	3
21	Liver Activation of Hepatocellular Nuclear Factor-4 $\hat{\pm}$ by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 361-370.	5.1	47
22	Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation. <i>Nature Communications</i> , 2020, 11, 3671.	12.8	17
23	Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 38.	5.2	12
24	Withanolide Metabolites Inhibit PI3K/AKT and MAPK Pro-Survival Pathways and Induce Apoptosis in Acute Myeloid Leukemia Cells. <i>Biomedicines</i> , 2020, 8, 333.	3.2	10
25	Cancer Burden Is Controlled by Mural Cell- $\hat{2}$ 3-Integrin Regulated Crosstalk with Tumor Cells. <i>Cell</i> , 2020, 181, 1346-1363.e21.	28.9	53
26	Prediction of Signed Protein Kinase Regulatory Circuits. <i>Cell Systems</i> , 2020, 10, 384-396.e9.	6.2	23
27	Cancer associated fibroblast FAK regulates malignant cell metabolism. <i>Nature Communications</i> , 2020, 11, 1290.	12.8	95
28	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 1267-1282.	7.3	37
29	Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring. <i>Nature Biotechnology</i> , 2020, 38, 493-502.	17.5	72
30	A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. <i>British Journal of Cancer</i> , 2020, 123, 542-555.	6.4	22
31	PARP-1 activation after oxidative insult promotes energy stress-dependent phosphorylation of YAP1 and reduces cell viability. <i>Biochemical Journal</i> , 2020, 477, 4491-4513.	3.7	9
32	Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
33	Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells. <i>Experimental Eye Research</i> , 2019, 188, 107790.	2.6	6
34	Perineural invasion in pancreatic cancer: proteomic analysis and <i>in vitro</i> modelling. <i>Molecular Oncology</i> , 2019, 13, 1075-1091.	4.6	38
35	Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5959.	4.1	28
36	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. <i>PLoS Biology</i> , 2019, 17, e3000554.	5.6	13

#	ARTICLE	IF	CITATIONS
37	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
38	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
39	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
40	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
41	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
42	Dynamic trafficking and turnover of JAM-C is essential for endothelial cell migration. , 2019, 17, e3000554.		0
43	Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. <i>Oncogene</i> , 2018, 37, 3216-3228.	5.9	60
44	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. <i>Cell Reports</i> , 2018, 22, 2469-2481.	6.4	34
45	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2018, 32, 1818-1822.	7.2	36
46	Phosphoproteomics-Based Profiling of Kinase Activities in Cancer Cells. <i>Methods in Molecular Biology</i> , 2018, 1711, 103-132.	0.9	24
47	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	9.4	255
48	Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility. <i>Nature Communications</i> , 2018, 9, 4826.	12.8	53
49	Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets. <i>Cancers</i> , 2018, 10, 334.	3.7	41
50	Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway. <i>Blood</i> , 2018, 132, 588-588.	1.4	0
51	Approaches to identify kinase dependencies in cancer signalling networks. <i>FEBS Letters</i> , 2017, 591, 2577-2592.	2.8	11
52	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2017, , .	7.2	0
53	Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1694-1704.	3.8	18
54	Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1. <i>Scientific Reports</i> , 2017, 7, 4956.	3.3	6

#	ARTICLE	IF	CITATIONS
55	Impact of phosphoproteomics in the translation of kinase-targeted therapies. <i>Proteomics</i> , 2017, 17, 1600235.	2.2	28
56	Label-Free Phosphoproteomic Approach for Kinase Signaling Analysis. <i>Methods in Molecular Biology</i> , 2017, 1636, 199-217.	0.9	10
57	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 15648-15661.	1.8	13
58	NCK Associated Protein 1 Modulated by miRNA-214 Determines Vascular Smooth Muscle Cell Migration, Proliferation, and Neointima Hyperplasia. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	50
59	Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. <i>Nature</i> , 2016, 537, 544-547.	27.8	443
60	Disulfide-activated protein kinase G β regulates cardiac diastolic relaxation and fine-tunes the Frank-Starling response. <i>Nature Communications</i> , 2016, 7, 13187.	12.8	46
61	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
62	Application of Proteomics in Cancer Biomarker Discovery: GeLC-MS/MS. <i>Methods in Molecular Biology</i> , 2016, 1381, 201-209.	0.9	1
63	The MAP kinase pathway coordinates crossover designation with disassembly of synaptonemal complex proteins during meiosis. <i>ELife</i> , 2016, 5, e12039.	6.0	36
64	Empirical inference of circuitry and plasticity in a kinase signaling network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7719-7724.	7.1	69
65	Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data. <i>Nature Communications</i> , 2015, 6, 8033.	12.8	79
66	ERK and RSK are necessary for TRH-induced inhibition of r-ERG potassium currents in rat pituitary GH 3 cells. <i>Cellular Signalling</i> , 2015, 27, 1720-1730.	3.6	5
67	Role of phosphoproteomics in the development of personalized cancer therapies. <i>Proteomics - Clinical Applications</i> , 2015, 9, 383-395.	1.6	40
68	The urinary proteome and metabolome differ from normal in adults with mitochondrial disease. <i>Kidney International</i> , 2015, 87, 610-622.	5.2	41
69	Cross-species Proteomics Reveals Specific Modulation of Signaling in Cancer and Stromal Cells by Phosphoinositide 3-kinase (PI3K) Inhibitors. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1457-1470.	3.8	24
70	Environmental Stress Affects the Activity of Metabolic and Growth Factor Signaling Networks and Induces Autophagy Markers in MCF7 Breast Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 836-848.	3.8	33
71	Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. <i>Biochemical Society Transactions</i> , 2014, 42, 791-797.	3.4	5
72	Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. <i>Genome Biology</i> , 2013, 14, R37.	9.6	60

#	ARTICLE	IF	CITATIONS
73	Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth. <i>Biochemical Journal</i> , 2013, 450, 619-628.	3.7	21
74	Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells. <i>Science Signaling</i> , 2013, 6, rs6.	3.6	298
75	Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 453-466.	3.8	62
76	Global profiling of protein kinase activities in cancer cells by mass spectrometry. <i>Journal of Proteomics</i> , 2012, 77, 492-503.	2.4	12
77	Advances in phosphopeptide enrichment techniques for phosphoproteomics. <i>Amino Acids</i> , 2012, 43, 1009-1024.	2.7	100
78	Characterization of a TiO ₂ enrichment method for label-free quantitative phosphoproteomics. <i>Methods</i> , 2011, 54, 370-378.	3.8	101
79	A Self-validating Quantitative Mass Spectrometry Method for Assessing the Accuracy of High-content Phosphoproteomic Experiments. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.003079.	3.8	49
80	Biological signalling activity measurements using mass spectrometry. <i>Biochemical Journal</i> , 2011, 434, 189-199.	3.7	31
81	Approaches and Applications of Quantitative LC-MS for Proteomics and Activitomics. <i>Methods in Molecular Biology</i> , 2010, 658, 3-17.	0.9	10
82	Analysis of Peptides in Biological Fluids by LC-MS/MS. <i>Methods in Molecular Biology</i> , 2010, 658, 311-321.	0.9	4
83	Quantitative Profile of Five Murine Core Proteomes Using Label-free Functional Proteomics. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1560-1573.	3.8	105